KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) Return on Equity (2016 - 2025)

Historic Return on Equity for Inovio Pharmaceuticals (INO) over the last 15 years, with Q3 2025 value amounting to 8.35%.

  • Inovio Pharmaceuticals' Return on Equity fell 70200.0% to 8.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.35%, marking a year-over-year decrease of 70200.0%. This contributed to the annual value of 1.16% for FY2024, which is 3600.0% down from last year.
  • Latest data reveals that Inovio Pharmaceuticals reported Return on Equity of 8.35% as of Q3 2025, which was down 70200.0% from 2.32% recorded in Q2 2025.
  • Inovio Pharmaceuticals' Return on Equity's 5-year high stood at 0.25% during Q2 2021, with a 5-year trough of 8.35% in Q3 2025.
  • Moreover, its 5-year median value for Return on Equity was 1.14% (2022), whereas its average is 1.47%.
  • In the last 5 years, Inovio Pharmaceuticals' Return on Equity soared by 9400bps in 2021 and then crashed by -70200bps in 2025.
  • Inovio Pharmaceuticals' Return on Equity (Quarter) stood at 0.71% in 2021, then plummeted by -60bps to 1.14% in 2022, then grew by 7bps to 1.06% in 2023, then plummeted by -44bps to 1.52% in 2024, then plummeted by -450bps to 8.35% in 2025.
  • Its Return on Equity stands at 8.35% for Q3 2025, versus 2.32% for Q2 2025 and 1.7% for Q1 2025.